Trials / Completed
CompletedNCT02107872
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1500 | |
| DRUG | placebo |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2014-04-08
- Last updated
- 2015-09-30
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02107872. Inclusion in this directory is not an endorsement.